Bone Biologics Co. (NASDAQ:BBLGW) Short Interest Up 44.4% in April

Bone Biologics Co. (NASDAQ:BBLGW) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,300 shares, an increase of 44.4% from the March 31st total of 900 shares. Based on an average trading volume of 1,800 shares, the short-interest ratio is currently 0.7 days.

Bone Biologics Stock Down 4.5 %

BBLGW stock traded down $1.04 during trading on Friday, reaching $22.00. 1,654 shares of the stock were exchanged, compared to its average volume of 2,960. Bone Biologics has a twelve month low of $0.43 and a twelve month high of $44.15. The stock has a 50 day simple moving average of $15.46 and a 200-day simple moving average of $8.44.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.